TNF and rheumatoid arthritis: An FDA-sanctioned post-marketing Oral Rheumatoid Arthritis Trial (ORAL) Surveillance comparing the JAK inhibitor tofacitinib with anti-TNF therapy in patients with rheumatoid arthritis aged 50 years or older with at least one cardiovascular risk factor demonstrated a higher incidence of cardiovascular and oncological diseases, as well as different forms of herpes infection, when using tofacitinib in patients 65 years of age and older, while the drugs showed equivalent efficacy [199].